soul trial oral semaglutide cardiovascular outcomes 2025 results Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π Oral Semaglutide's Impact on Cardiovascular
Description
Phase 2 trial data showed that participants who followed a proper escalation schedule consistently reported better tolerance and lower discontinuation rates than the trial aggregate suggests
doi:10.1111/bph.12490 62
Central appetite regulation : GLP-1 receptors are present in the hypothalamus and other brain regions involved in appetite control, leading to reduced caloric intake and weight loss
A nasogastric tube is inserted if ileus develops
(verified owner) Rated 5 out of 5 Melissa Singletary (verified owner) Rated 5 out of 5 Thank you for your quick service
